Skip to main content

Talaris Therapeutics, Inc. (TALS)

NASDAQ: TALS · IEX Real-Time Price · USD
15.75 0.05 (0.32%)
Oct 25, 2021 4:00 PM EDT - Market closed
Market Cap670.80M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out27.37M
EPS (ttm)-2.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,373
Open15.70
Previous Close15.70
Day's Range14.90 - 16.12
52-Week Range11.39 - 19.82
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About TALS

Talaris Therapeutics is a late-clinical stage, cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation (allo-HSCT) that we believe has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. In the organ transplant setting, which is our initial focus, we believe our proprietary therapeutic approach, which we call Facilitated Allo-HSCT Therapy, could prevent organ re...

IndustryBiotechnology
IPO DateMay 7, 2021
CEOScott Requadt
Employees91
Stock ExchangeNASDAQ
Ticker SymbolTALS
Full Company Profile

Financial Performance

Financial Statements

News

Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences

BOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform ...

1 month ago - GlobeNewsWire

Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

4 months ago - GlobeNewsWire

Talaris Therapeutics Announces Closing of Initial Public Offering

BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

5 months ago - GlobeNewsWire

Talaris Therapeutics Announces Pricing of Initial Public Offering

BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of c...

5 months ago - GlobeNewsWire

Talaris Therapeutics IPO Registration Document (S-1)

Talaris Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC